map2

Every compound in the sci-wiki that affects map2; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

1 sourced · 1 reference

←map22/2

Nootropic

Pregnenolone

Pregnenolone (3β-hydroxypregn-5-en-20-one) is an endogenous neurosteroid and the first steroid synthesized from cholesterol, making it the obligatory precursor of every other steroid hormone, including progesterone, dehydroepiandrosterone (DHEA), cortisol, the sex steroids, and the neuroactive metabolites allopregnanolone and pregnenolone sulfate. Once regarded as a metabolically inert intermediate, it is now recognized as a signaling molecule in its own right, most notably as an endogenous negative allosteric modulator of the type-1 cannabinoid receptor (CB1, the principal brain receptor for THC) and as a ligand for microtubule-associated protein 2 (MAP2, a neuronal cytoskeletal scaffolding protein), through which it promotes microtubule assembly and neurite outgrowth. Synthesized de novo in the brain by neurons and glia, it is investigated as an adjunctive treatment for schizophrenia, mood disorders, and cannabis-related conditions, and is sold over the counter as a nootropic and hormonal supplement.

3 outlets

reference shelf; no outlet carries these yet

Nootropic

MAP4343

MAP4343 (3β-methoxypregnenolone) is a synthetic derivative of the endogenous neurosteroid pregnenolone in which the 3β-hydroxyl group is replaced by a methyl ether, developed by the French steroid pharmacologist Étienne-Émile Baulieu and the biotechnology company Mapreg. Unlike classical neurosteroids that modulate ligand-gated ion channels, MAP4343 acts on microtubule-associated protein 2 (MAP2; a structural protein that governs the assembly and stability of neuronal microtubules), where it promotes tubulin polymerization and restores microtubule dynamics. It has been investigated as a novel, mechanistically distinct antidepressant and anti-addiction candidate, showing rapid and durable antidepressant-like effects in rodent and tree shrew stress models and having advanced into early clinical development. As of the mid-2020s it remains an investigational agent without regulatory approval.

reference